Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5923381 | 0.88 | MAPT (0.55) | S1PR1S1PR3MAPTTP53KDM4E | |
| SCHEMBL5923063 | 0.87 | MAPT (0.54) | S1PR1S1PR3MAPTTP53KDM4E | |
| SCHEMBL5923002 | 0.85 | MAPT (0.57) | MAPTTP53KDM4EHPGDHTT | |
| SCHEMBL5923549 | 0.84 | SPHK1 (0.47) | S1PR1S1PR3MAPTALDH1A1 | |
| SCHEMBL5923088 | 0.82 | MAPT (0.48) | S1PR1S1PR3MAPTTP53KDM4E | |
| SCHEMBL5922968 | 0.81 | MAPT (0.62) | MAPTTP53KDM4EHPGDHTT | |
| SCHEMBL4983215 | 0.80 | PTGES (0.56) | S1PR1S1PR3GAAL3MBTL1FAAH | |
| SCHEMBL13310313 | 0.80 | MAPT (0.52) | MAPTTP53KDM4EHPGDHTT | |
| SCHEMBL5923222 | 0.79 | NPSR1 (0.49) | MAPTHPGDHTTHSD17B10ALDH1A1 | |
| Bromide SCHEMBL5458791 | 0.79 | PTGES (0.55) | S1PR1S1PR3GAAL3MBTL1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | claimed |
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | PIGS, GUCY1A1, GUCY1B1 | S1PR1 544/4885S1PR3 502/4885MAPT 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.